73 companies only 4 losses
Compared to other pharmaceutical industry segments, the medical device industry is relatively stable, in the 73 listed companies, 69 in the first half of the year to achieve profits, only 4 losses, 50 companies to achieve first half of the year net profit year-on-year increase, of which there are 5 The year-on-year increase of more than 1,000%, respectively, for the Ingenics Medical (2611.87%), Kangtai Medical (1820.05%), Zhende Medical (1544.74%), Oriental Biological (1477.45%), D'an Genetics (1186.48%).
In addition, in the first half of the year *** there are four medical device companies in the loss, respectively, Tianzhihang (-34.066 million yuan), Bohui Innovation (-15.9511 million yuan), Turbogeneration Life (-8.612 million yuan), Lidman (-5.9576 million yuan).
Part of the medical device company's performance growth is not unrelated to the outbreak of the epidemic, the new crown epidemic, the domestic and foreign demand for respiratory machines, masks, in vitro diagnostic products, etc. increased significantly. To Merry Medical, for example, as China's largest medical equipment and solutions provider, its "earning power" is beyond doubt, the epidemic has also become an important factor, the company's first half of life information and support business of the monitor, ventilator, infusion pumps, medical imaging business of portable ultrasound, mobile DR and other products directly related to the epidemic Growth accelerated to varying degrees. Among them, the new crown epidemic on the life information and support business of the pulling effect is particularly significant.
This drive is industry-wide, in order to enhance the screening and treatment capacity of infectious diseases, while preventing and controlling the second outbreak of the epidemic, the domestic market since March has entered the stage of increasing the construction of critical ICUs, infectious disease hospitals, fever outpatient clinics and other aspects of the new medical infrastructure, the governments around the world have begun to prepare for the relevant anti-epidemic equipment and supplies for the strategic reserve, which is good news for the industry. The development of the industry is undoubtedly good news.
High growth, small scale coexist
At present, China's medical device industry is growing rapidly, and has become the second largest market in the world. Public data show that in 2018, the main revenue of China's medical device manufacturers was about 638 billion yuan, and from 2021 to 2022, the main revenue of medical device manufacturers will be expected to exceed one trillion yuan, China's medical device industry CAGR continues to maintain at about 15%, and China's market will maintain a high-speed expansion trend for a period of time in the future.
This is also reflected in the listed companies. Among the 73 medical device companies, 45 realized year-on-year revenue growth, Contai Medical, Zhende Medical, Oriental Biological, Shuoshi Biological, Ingenics Medical, Daan Genetics revenue year-on-year increase in the top rankings, are more than 300%, of which Contai Medical, Zhende Medical revenue year-on-year increase of more than 400%, Contai Medical to 421.17% of the year-on-year increase in revenue to the top of the list, Zhende Medical with a 401.24% followed by Zhende Medical with 421.17% year-on-year revenue increase.
In the 29 companies with year-on-year revenue decline, Haohai BioScience realized revenue of 496 million yuan in the first half of the year, a year-on-year decline of 36.85%, becoming the largest revenue decline in the company, Turbogeneration Life, Lidman, and good medical, beauty of the Kang Biological, Nine Strong Biological, and the love of the medical revenue decline in more than 20%.
At the same time, China's medical device companies are also facing the status quo of small scale and low industry concentration. The Medical Device Blue Book: China Medical Device Industry Development Report (2019) shows that more than 90% of China's medical device manufacturers are small and medium-sized enterprises, with an annual average main revenue of 30-40 million yuan, compared with the annual average main revenue of 300-400 million yuan of enterprises in the domestic pharmaceutical industry, there is still a significant The gap.
Proofread by Liu Baoqing